Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-211"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20101124.15.3-211"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"In today’s sitting, we voted at first reading on the proposal for a regulation of the European Parliament and the Council as regards information on medicinal products (EU procedures for the authorisation and supervision of medicinal products). Parliament and patient organisations have been asking for such a proposal for a long time, in order to enable patients to better informed on the medicines they are prescribed and taking.
The current regulation is not in line with technical development or the possibilities and challenges created by Internet. Patients in Europe already have infinite access to uncontrolled and often incorrect information about prescription-only pharmaceutical products in a few seconds.
The rapporteur proposed to shift the focus of the proposal and to mandate pharmaceutical companies to provide certain information to the patients and thus, to put the ‘patients’ right to know’ at the centre of the legislation. Increased access to quality information will contribute to achieving better health outcomes for patients as better informed patients are more likely to continue necessary treatments and better understand decisions related to their treatment. The proposal will therefore bring an added value."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples